The Role of N-Acetylcysteine as Adjuvant Therapy on TGF-β and II-6-Mediated Immune Response and Subsequent Fibrosis in Covid-19 Patients Predicted by Crp and D-Dimer Levels Article Sidebar

Background: Despite vast amount of completed and ongoing researches, the role immune system in COVID-19 remains unclear. Widespread lung damage as result disease also often causes pulmonary fibrosis a sequela. Antioxidant property N-Acetylcysteine (NAC) has prompted its use adjuvant therapy COVID-19, both regulation prevention fibrosis. We analyze high dose NAC (>1200 mg/day) response, mediated by major pro-inflammatory cytokines IL-6 TGF-β, preventing subsequent fibrosis, predicted CRP D-dimer, known parameters COVID-19. Premature increase TGF-β may play dysregulation Method This is non-equivalent experimental study confirmed COVID patients admitted our hospital between June 2020 to July 2021. Patients were randomly divided unto control group, IL-6, D-dimer levels measured at admission after 7 days administration NAC. Result Compared there are significant decreases CRP, (p=.001, .000, 0.001, respectively) administration. level increases although not significantly. Conclusion beneficial adjunctive alleviating response it lowers level. levels, which suggests that prevent post mitigating caused disease.